We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.59%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$17.8M
Cap. Flow
% of AUM
-10.58%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$947K |
| 2 |
Moderna
MRNA
|
+$899K |
| 3 |
Meta Platforms (Facebook)
META
|
+$895K |
| 4 |
Netflix
NFLX
|
+$876K |
| 5 |
Chipotle Mexican Grill
CMG
|
+$852K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$1.01M |
| 2 |
Progressive
PGR
|
+$999K |
| 3 |
Stryker
SYK
|
+$984K |
| 4 |
Republic Services
RSG
|
+$973K |
| 5 |
Linde
LIN
|
+$966K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DAWN
401
DELISTED
Day One Biopharmaceuticals
DAWN
| $96.4K | 0.06% |
8,073
+3,388
| +72% | +$44.2K |
|
|
RAPT
402
DELISTED
RAPT Therapeutics
RAPT
| $96.4K | 0.06% |
644
-44
| -6% | -$6.85K |
|
|
ETNB
403
DELISTED
89bio
ETNB
| $96.3K | 0.06% |
+5,084
| New | +$89.3K |
|
404
Crinetics Pharmaceuticals
CRNX
$8.87B
| $96.1K | 0.06% |
5,333
-882
| -14% | -$17.6K |
|
|
AMRS
405
DELISTED
Amyris Inc.
AMRS
| $95.7K | 0.06% |
92,939
+35,454
| +62% | +$33K |
|
406
Fate Therapeutics
FATE
$283M
| $95.3K | 0.06% |
20,025
+13,440
| +204% | +$74.2K |
|
407
Rocket Pharmaceuticals
RCKT
$355M
| $95.2K | 0.06% |
4,792
+351
| +8% | +$7.09K |
|
|
AGEN
408
Agenus
AGEN
$255M
| $95.1K | 0.06% |
2,971
+1,054
| +55% | +$33.7K |
|
409
AbCellera Biologics
ABCL
$1.6B
| $95.1K | 0.06% |
14,714
+4,731
| +47% | +$32.3K |
|
410
Viridian Therapeutics
VRDN
$2.18B
| $93.5K | 0.06% |
3,930
+307
| +8% | +$7.87K |
|
|
EXAI
411
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $92.8K | 0.06% |
+15,668
| New | +$96.1K |
|
412
Stoke Therapeutics
STOK
$1.83B
| $92.2K | 0.05% |
8,678
-3,400
| -28% | -$36.2K |
|
|
AKRO
413
DELISTED
Akero Therapeutics
AKRO
| $92K | 0.05% |
1,971
-318
| -14% | -$14.6K |
|
414
Arvinas
ARVN
$530M
| $91.8K | 0.05% |
3,699
+1,011
| +38% | +$26K |
|
415
Ardelyx
ARDX
$1.25B
| $91.7K | 0.05% |
+27,049
| New | +$111K |
|
|
ACLX
416
DELISTED
Arcellx
ACLX
| $90.6K | 0.05% |
2,866
-202
| -7% | -$7.72K |
|
417
4D Molecular Therapeutics
FDMT
$543M
| $89K | 0.05% |
4,923
+783
| +19% | +$14.4K |
|
418
ALX Oncology
ALXO
$272M
| $88.6K | 0.05% |
11,794
+2,775
| +31% | +$18.2K |
|
419
Edgewise Therapeutics
EWTX
$4.48B
| $88.5K | 0.05% |
11,422
-1,085
| -9% | -$9.15K |
|
420
Scilex Holding
SCLX
$49.4M
| $88.4K | 0.05% |
504
| – | – |
|
421
Iovance Biotherapeutics
IOVA
$2.19B
| $88.3K | 0.05% |
12,542
-2,467
| -16% | -$17.7K |
|
422
Aldeyra Therapeutics
ALDX
$95.6M
| $87.3K | 0.05% |
+10,401
| New | +$102K |
|
423
Seres Therapeutics
MCRB
$47M
| $85.1K | 0.05% |
888
+71
| +9% | +$7.73K |
|
424
Alector
ALEC
$168M
| $84.8K | 0.05% |
14,104
+3,322
| +31% | +$23.2K |
|
425
Kodiak Sciences
KOD
$2.62B
| $83.1K | 0.05% |
12,042
-1,838
| -13% | -$11.2K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, Virtus ETF Advisers held 495 positions worth $169M, down 7.2% from $182M the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.
Virtus ETF Advisers withdrew a net $17.8M in Q2 2023, closing 60 positions and reducing 257 holdings. Its most notable exit was Activision Blizzard, an estimated $1.01M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in NVIDIA worth $1.21M.
- Virtus ETF Advisers's largest Q2 2023 buy was NVIDIA: 28,520 shares worth $1.21M.
- Virtus ETF Advisers added most to Moderna in Q2 2023, an estimated $899K increase.
- Virtus ETF Advisers's biggest Q2 2023 reduction was Dow Inc, cutting an estimated $898K.
- Virtus ETF Advisers fully exited Activision Blizzard in Q2 2023, selling an estimated $1.01M.
- Virtus ETF Advisers's ten largest holdings make up 6.3% of its $169M portfolio in Q2 2023.
- Virtus ETF Advisers opened 55 new positions and closed 60 in Q2 2023.
- Virtus ETF Advisers's portfolio value fell 7.2% quarter-over-quarter to $169M.
Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.